Advisor Group’s Epizyme EPZM Stock Holding History
Bought
Maintained
Sold
Other funds holding EPZM
Advisor Group's EPZM Position: Q4 2019 in Review
Advisor Group reduced its Epizyme (EPZM) stake by 46% in Q4 2019, selling an estimated $1.87K and leaving 145 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #4800.
Advisor Group first reported a position in EPZM in Q3 2016 and has held it in 8 quarters since. The position peaked at $26K in Q3 2016. 136 funds tracked by Wall St. Rank hold EPZM as of Q4 2019.
- Advisor Group held 145 shares of Epizyme worth $4K as of Q4 2019.
- Advisor Group sold 126 Epizyme shares in Q4 2019, an estimated $1.87K.
- Epizyme made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4800 holding.
- Advisor Group first reported a position in Epizyme in Q3 2016 and has held it in 8 quarters since.
- Advisor Group's Epizyme position peaked at $26K in Q3 2016.
- 136 funds tracked by Wall St. Rank held Epizyme as of Q4 2019.
Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.